Retinoic acid therapy in patients with radioiodine negative differentiated thyroid cancer and clinical or biochemical evidence of disease: An initial experience
Open Access
- 1 January 2011
- journal article
- research article
- Published by Medknow in Indian Journal of Nuclear Medicine
- Vol. 26 (3), 144-8
- https://doi.org/10.4103/0972-3919.103997
Abstract
Background: Dedifferentiation of thyroid follicular cells renders radioiodine therapy ineffective in patients of differentiated thyroid cancer (DTC). An alternative therapy to treat the disease or reinduce radioiodine uptake is necessary. Materials and Methods: We evaluated the role of retinoic acid therapy in 13 cases of DTC with raised thyroglobulin and/or clinically evident disease. Retinoic acid was given in a dose of 1.5 mg/kg for a period ranging between 1.5 and 18 months. Results: Age of the patients was between 18 and 65 years with a median of 49 years. Ten patients had papillary while two had follicular and one patient had mixed papillary and follicular thyroid cancer. Mean radioiodine given before starting retinoic acid was 164 mCi. Mean duration of therapy was 6.4 months. Thyroglobulin decreased in 2 patients and increased in 11 patients at the end of therapy. Radioiodine uptake was demonstrable in six patients, though faintly, while 7 cases showed no uptake. Based on the clinical and biochemical parameters, four patients had progressive disease, eight had stable disease and one patient showed partial response. Of the six patients with reinduction of radioiodine uptake, three had biochemical progression and the other three had stable disease. Conclusion: Our findings suggest that retinoic acid therapy may induce radioiodine uptake and reduce serum thyroglobulin levels in some patients with DTC, but whether this results in clinically significant response can only be ascertained on long-term follow-up.Keywords
This publication has 30 references indexed in Scilit:
- 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 studyThyroid Research, 2009
- Differentiated Thyroid Carcinoma with Distant Metastases: Probability of Survival and Its Predicting FactorsCancer Biotherapy & Radiopharmaceuticals, 2007
- A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancerNuclear Medicine Communications, 2007
- Defective Efficacy of Retinoic Acid Treatment in Patients with Metastatic Thyroid CarcinomaThyroid®, 2006
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumActa Endocrinologica, 2006
- Treatment concepts of acute promyelocytic leukemiaCritical Reviews in Oncology/Hematology, 2005
- Retinoic Acid Increases Sodium/Iodide Symporter mRNA Levels in Human Thyroid Cancer Cell Lines and Suppresses Expression of Functional Symporter in Nontransformed FRTL-5 Rat Thyroid CellsBiochemical and Biophysical Research Communications, 1997
- Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical resultsExperimental and Clinical Endocrinology & Diabetes, 1996
- Surgical reintervention for differentiated thyroid cancerBritish Journal of Surgery, 1993
- The responsiveness of bone metastases to radiotherapy: The effect of site, histology and radiation dose on pain reliefRadiotherapy and Oncology, 1989